Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
Public ClinicalTrials.gov record NCT00743652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.
Study identification
- NCT ID
- NCT00743652
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 373 participants
Conditions and interventions
Interventions
- 13-valent Pneumococcal Conjugate Vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 42 Days to 5 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2008
- Primary completion
- Aug 31, 2010
- Completion
- Aug 31, 2010
- Last update posted
- Mar 14, 2012
2009 – 2010
United States locations
- U.S. sites
- 21
- U.S. states
- 1
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Akiak | Alaska | 99552 | — |
| Pfizer Investigational Site | Bethel | Alaska | 99559 | — |
| Pfizer Investigational Site | Chefornak | Alaska | 99561 | — |
| Pfizer Investigational Site | Chevak | Alaska | 99563 | — |
| Pfizer Investigational Site | Eek | Alaska | 99578 | — |
| Pfizer Investigational Site | Emmonak | Alaska | 99581 | — |
| Pfizer Investigational Site | Hooper Bay | Alaska | 99604 | — |
| Pfizer Investigational Site | Kalskag | Alaska | 99607 | — |
| Pfizer Investigational Site | Kasigluk | Alaska | 99609 | — |
| Pfizer Investigational Site | Kongiganak | Alaska | 99545 | — |
| Pfizer Investigational Site | Kotlik | Alaska | 99620 | — |
| Pfizer Investigational Site | Kwethluk | Alaska | 99621 | — |
| Pfizer Investigational Site | Kwigillingok | Alaska | 99622 | — |
| Pfizer Investigational Site | Mountain Village | Alaska | 99632 | — |
| Pfizer Investigational Site | Napaskiak | Alaska | 99559 | — |
| Pfizer Investigational Site | Newtok | Alaska | 99559 | — |
| Pfizer Investigational Site | Nunapitchuk | Alaska | 99641 | — |
| Pfizer Investigational Site | Russian Mission | Alaska | 99657 | — |
| Pfizer Investigational Site | Scammon Bay | Alaska | 99662 | — |
| Pfizer Investigational Site | Toksook Bay | Alaska | 99637 | — |
| Pfizer Investigational Site | Tuluksak | Alaska | 99679 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00743652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00743652 live on ClinicalTrials.gov.